BioSpace

Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease

Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.

Por BioSpace

1 minuto de lectura
Compartir
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas